Experimental Procedures and Items, Investigational Devices, and Clinical Trials | UHC Coverage Update

TL;DR: UnitedHealthcare modified its experimental, investigational, and clinical trials coverage policy for Medicare Advantage members, effective September 26, 2025. Here's what billing teams need to know about IDE studies, Category A and B devices, and routine cost coverage under this updated policy.

UnitedHealthcare updated its Medicare Advantage medical policy governing experimental procedures, investigational devices, and clinical trials. This policy — coded as experimental-investigational-clinical-trials in the UHC system — clarifies how the UHC experimental investigational clinical trials UHC system assigns financial responsibility between the Medicare Advantage Organization (MAO) and CMS for IDE studies and routine trial costs. No specific CPT or HCPCS codes are listed in this policy. The financial exposure is high, and the rules around who pays for what are easy to misread.

---

Quick-Reference Table

Field	Detail Copy
Payer	UnitedHealthcare (Medicare Advantage)
Policy	Experimental Procedures and Items, Investigational Devices, and Clinical Trials – Medicare Advantage Medical Policy
Policy Code	experimental-investigational-clinical-trials
Change Type	Modified
Effective Date	September 26, 2025
Impact Level	High
Specialties Affected	Oncology, cardiology, neurology, clinical research sites, any provider enrolling MA members in IDE studies or approved clinical trials
Key Action	Verify CMS approval status for any IDE study before billing the MAO — and confirm whether the device is Category A or Category B before submitting claims

---

UnitedHealthcare Experimental and Investigational Coverage Policy and Medical Necessity Requirements 2025

The core rule here is simple, but the exceptions are where billing teams get into trouble. Under this UHC coverage policy, experimental and investigational procedures, items, and medications do not meet the medical necessity standard. That means they are not Reasonable and Necessary under Medicare rules — and claims for them will deny.

The two main exceptions are IDE studies and approved clinical trials. Each has its own payment rules, and the MAO's responsibility depends entirely on CMS approval status and device category.

For clinical trials, UnitedHealthcare follows the Medicare coverage policy exactly: routine costs associated with Medicare-approved clinical trials are Medicare's financial responsibility. This means you bill traditional Medicare fee-for-service for routine care costs in those trials — not the MA plan. Billing the MAO directly for these costs is a common error that produces avoidable claim denial.

Medical necessity is the threshold question for everything in this policy. If a procedure or item hasn't cleared the experimental designation, there is no path to reimbursement through the MA plan. No prior authorization will fix that. Document early, verify CMS approval status before the patient is enrolled, and don't assume that because a trial exists, the costs are billable to UHC.

---

UnitedHealthcare IDE Study Coverage Policy: Category A vs. Category B Devices

This is where the policy gets specific — and where billing errors are most expensive. The Category A vs. Category B distinction determines what the MAO will pay for. Get this wrong and you're looking at significant claim denial exposure.

Category A (Experimental) Devices

A Category A device is one where the FDA hasn't resolved basic questions of safety and effectiveness. CMS will not approve Category A devices for coverage — they are statutorily excluded. Full stop.

What the MAO will pay for in a CMS-approved Category A IDE study is the routine care items and services — but only those that are covered by the Medicare Administrative Contractor (MAC) with jurisdiction over the MA plan's service area. The device itself is not covered, period. If your team bills for a Category A device, the claim will deny. Bill only for the routine care.

To get coverage of routine care in a Category A IDE study, CMS must have approved the study. Check the CMS Coverage website (cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html) and the Federal Register. If the study isn't listed there, the MAO has no obligation to pay — not even for routine care.

Category B (Nonexperimental/Investigational) Devices

A Category B device has cleared the initial safety and effectiveness bar. Other manufacturers may already have FDA premarket approval for the same device type, or the incremental risk is the remaining question — not foundational safety.

Here the MAO's responsibility is broader. UnitedHealthcare, as the MAO, pays for both the routine care items and services and the CMS-approved Category B device in a CMS-approved Category B IDE study. This is meaningfully different from Category A. Know which category you're dealing with before you build your billing approach for any study involving MA members.

The MAC still matters here. Coverage is based on what the MAC with jurisdiction over the MA plan's service area covers. This creates a local coverage determination (LCD) dependency — if the MAC doesn't cover a routine care item, the MAO doesn't have to pay it either.

---

Coverage Indications at a Glance

---

UnitedHealthcare Experimental and Investigational Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Experimental and Investigational Procedures Under experimental-investigational-clinical-trials

This policy does not list specific CPT, HCPCS, or ICD-10 codes. Coverage determinations under this policy are made at the study and device-category level — not at the procedure code level.

That said, your claims for routine care in IDE studies will carry the procedure codes for the actual services rendered. Those codes need to align with what the MAC covers in your jurisdiction. The absence of a specific code list in this policy does not reduce your billing risk — it shifts the due diligence to you.

When submitting claims for IDE study participants, consider the following documentation anchors drawn from the policy:

• CMS approval confirmation for the IDE study
• Device category designation (A or B)
• MAC jurisdiction documentation
• Clinical trial qualifier modifiers where applicable under Medicare billing rules

Work with your MAC and review the three CMS manuals cited in this policy:

• Medicare Benefit Policy Manual, Chapter 14, §20 (FDA-Approved IDE Studies)
• Medicare Claims Processing Manual, Chapter 32, §68 (IDE Studies)
• Medicare Managed Care Manual, Chapter 4, §10.7.2 (Payment for IDE Studies)

These manuals contain the operative billing guidance. This UHC coverage policy largely incorporates them by reference.

---

The Real Issue Here

Most billing teams handle IDE study claims infrequently enough that the Category A / Category B distinction doesn't become muscle memory. That's exactly when errors happen. A claim for a Category A device lands on the MAO's desk, it denies, and then you're chasing an appeal on a claim that never had a coverage path to begin with.

The September 26, 2025 modification to this policy is a signal that UHC is tightening up its Medicare Advantage experimental and investigational billing guidelines. Read the policy as a checklist: CMS approval status first, device category second, MAC LCD coverage third, then route the claim correctly. Do those four things and your denial rate on these claims drops significantly.

If your organization is actively enrolling Medicare Advantage members in IDE studies, the reimbursement implications here are not small. Routine care costs across a study population add up fast. Get the routing right.

---